TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...

Additionally, beyond adapting existing drug combinations, cutting-edge therapies such as bispecific antibodies and CAR T-cell ...

QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

As Dr Voorhees mentioned in part 2, the definition of high-risk SMM has evolved over time and is subject to change in the ...